Science Current Events | Science News | Brightsurf.com
 

Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma

February 08, 2016

A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.

The study was lead be Dr. Jean Roy, a haematologist at the Maisonneuve-Rosemont Hospital and professor at the University of Montreal, between 2001 and 2010 with 92 newly diagnosed patients. Using an approach developed at Maisonneuve-Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41%, a record level using this strategy. Moreover, patients in complete remission six months after the allograft had a relapse-free survival rate of 60%. Overall, the autograft strategy followed by allograft resulted in relapse-free survival rates of 20-25% in the long term.

"In many hospitals, doctors have abandoned the use of allografts for multiple myeloma due to the risk of toxicity and relapse. Our results, on the other hand, have led us to offer the treatment to more patients, especially younger patients and those with poorer prognoses," said Dr. Roy.

The results of this research were published in the specialized journal Bone Marrow Transplantation.

Other encouraging data

Moreover, in the same study, the mortality rate associated with this treatment over ten years was 10%, an extremely low rate following a family donor allograft. And while 50% of patients experienced a relapse of their myeloma, the subsequent treatment showed marked efficacy: 50% of these patients were alive five years after the relapse.

Based on these results, a new study aiming to reduce rates of relapse and complications is currently underway at Maisonneuve-Rosemont Hospital, with still preliminary but very encouraging results.

###

The study was supported by the University of Montreal's William Brock Fund.

University of Montreal


Related Multiple Myeloma Current Events and Multiple Myeloma News Articles


Carnegie Mellon develops bio-mimicry method for preparing and labeling stem cells
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

Demand for radiotherapy will rise substantially over next 10 years
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

Combination therapy may be better than radiotherapy alone to treat aggressive brain cancer
Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

A new class of drug slows growth of castration-resistant prostate cancer cells
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina (MUSC) and others.

Three studies point to effectiveness of new therapies for multiple myeloma
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.

Multiple myeloma patient study shows promise for natural killer cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

New vaccine strategy better protects high-risk cancer patients from flu
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

Targeting protein homeostasis holds potential to treat solid tumors and blood cancers
The success of proteasome inhibitors such as VELCADE® (bortezomib) and Kyprolis® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer.

Personalized drug screening on horizon for multiple myeloma patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
More Multiple Myeloma Current Events and Multiple Myeloma News Articles

Multiple Myeloma Patient Handbook 2015 Edition

Multiple Myeloma Patient Handbook 2015 Edition
by International Myeloma Foundation


One of the most daunting aspects of being diagnosed with myeloma is learning about – and understanding – an unfamiliar disease that is quite complicated. This booklet provides an excellent overview of myeloma. Prepared by Dr. Brian G.M. Durie, it focuses on what to do when myeloma is first discovered, the tests you really need, initial treatment options, and supportive care and how to get it.

For more information about multiple myeloma please visit www.myeloma.org

A Lucky Life Interrupted: A Memoir of Hope

A Lucky Life Interrupted: A Memoir of Hope
by Tom Brokaw (Author)


NEW YORK TIMES BESTSELLER • WITH A NEW PREFACE BY THE AUTHOR • A powerful memoir of a dramatic year spent battling cancer and reflecting on a long, happy, and lucky life—from the bestselling author of The Greatest Generation, whose iconic career in journalism has spanned more than fifty years

Tom Brokaw has led a fortunate life, with a strong marriage and family, many friends, and a brilliant journalism career culminating in his twenty-two years as anchor of the NBC Nightly News and as bestselling author. But in the summer of 2013, when back pain led him to the doctors at the Mayo Clinic, his run of good luck was interrupted. He received shocking news: He had multiple myeloma, a treatable but incurable blood cancer. Friends had always referred to Brokaw’s “lucky...

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones
by Jim Tamkin MD FACP FACE (Author), Dave Visel (Author)


The definitive guide to living a longer, fuller life with myeloma The Myeloma Survival Guide makes sense of the difficult questions myeloma patients face, dealing with every aspect of life after diagnosis, from creating a wellness team to navigating treatment options to building a financial safety net. Jim Tamkin, MD, who lived with myeloma for 11 years, and Dave Visel share the insights they've gained as a doctor, patient, and caregiver, including: Everything you need to know about drugs and treatments, including stem cell transplants How to deal with the pain and side effects of chemotherapy, radiation, and surgery Insurance and tax benefits to save money and get you the care you deserve Take-charge tools you can use today to feel better tomorrow...

Multiple Myeloma: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Illustrated)

Multiple Myeloma: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Illustrated)


Multiple Myeloma - Enhanced Edition: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Annotated and Illustrated) provides you overall information about brain tumor. This book was written by Medical Professionals from National Cancer Institute with scientific details. You will learn the cause, risk factors, symptoms, treatments, etc that will helpful for both readers who are interesred in health and whoever have a member in family suffer from cancer. Moreover, this edition of the book includes;

- Eating Hints: Before, During, and After Cancer Treatment

- Follow-up Care After Cancer Treatment

- How To Find a Doctor or Treatment Facility If You Have Cancer

- Facing Forward: Life After Cancer Treatment

-...

In The Blood: The Faces of Multiple Myeloma Cancer

In The Blood: The Faces of Multiple Myeloma Cancer


It's in the blood. Multiple Myeloma,is the cancer that has no cure. I am living with my daughter's story, actually, my son-in-law's, who is living it every moment of every day. I have watched my daughter as she holds back tears in front of strangers, and lets the floodgates open sittings alone in the dark at night. She, as many of us do, anticipate their loved one dwindling before their eyes, wasting away in inches in the short lifespan drafted out by doctors' pens. But every day they hold the faith. Every day they praise God for His goodness, and every day they find a treasure in the family, community, and faith they hold so dear. Join us in their journey to find a cure. The stories here are original and real. They are the faces of Myeloma cancer. They are raw and unedited, and...

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know
by Chart-MD


Just the facts are included in this book. Written by a board certified medical oncologist, this is the perfect text if you are looking for a quick review of the information you need to know about multiple myeloma. We won’t waste your time with this rapid access information. The Multiple myeloma Study Guide has distilled the key details down to the concise facts that you will understand and remember.

The Multiple Myeloma Study Guide is an ideal resource for medical students and anyone who wants to understand more about Multiple myeloma.

Sample Text:

Fact: In the United States, the lifetime risk of getting multiple myeloma is 1 in 161 (0.62%).

Fact: Urinary monoclonal protein elevations in multiple myeloma are more likely to be...

NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2016

NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2016
by National Comprehensive Cancer Network® (NCCN®) (Author)


[OFFICIAL CURRENT VERSION] From the medical leaders of 27 of the world's most renowned cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to multiple myeloma. Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about the diagnosis and treatment of multiple myeloma. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! Part 1 - Multiple myeloma basics: Explains how and where this type of cancer starts. Part 2 - Testing for myeloma: Describes the tests...

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J. Heller (Author)


A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually.

Multiple Myeloma

Multiple Myeloma
by NetCE


Multiple myeloma is the second most prevalent hematologic cancer after non-Hodgkin lymphoma. While great strides have been made to improve survival rates with this disease, and positive outcomes have been attained over the last ten years, multiple myeloma remains an incurable disease. The purpose of this course is to provide healthcare professionals in contact with multiple myeloma patients the information necessary to provide optimum care, treatment, and patient education. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.

Upon completion of this course, you should be able to:

1. Review the history of multiple myeloma.
2. Describe the pathophysiology and differentiation of multiple...

High-Dose Chemotherapy with Stem Cell Rescue (The Understanding Series)

High-Dose Chemotherapy with Stem Cell Rescue (The Understanding Series)
by International Myeloma Foundation


This booklet explains the rationale for, and the process of receiving high-dose chemotherapy with stem cell rescue (also called stem cell transplant.)

© 2017 BrightSurf.com